Teva receives FDA approval for generic ADHD drug

Brand Adderall, made by Britain's Shire plc, had $2 billion in US sales in 2012.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has obtained US Food and Drug Administration (FDA) approval for its generic version of six dosages of Adderall XR capsules for the treatment of attention deficit hyperactivity disorder (ADHD). Brand Adderall, made by Britain's Shire plc (LSE: SHP; Nasdaq: SHPG) had $2 billion in US sales in 2012, according to IMS.

Teva currently sells a generic version of Adderall XR capsules under a 2006 license and distribution agreement with Shire, as part of a settlement of patent litigation between Shire and Teva subsidiary Barr Pharmaceuticals. Under the terms of the agreement, Teva has the right to be supplied product by Shire through April 1, 2014.

Published by Globes [online], Israel business news - - on February 14, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017